Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Vectalys logo — Pioneering excellence in gene delivery to empower groundbrea...

Vectalys

Pioneering excellence in gene delivery to empower groundbreaking scientific discovery and therapeutic development worldwide.

Founded 2005 Venture round Total: $5.00M Biotechnology, Health and Wellness +1

General Information

Company Name Vectalys
Founded Year 2005
Industries Biotechnology, Health and Wellness, Manufacturing
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Vectalys. To contact Vectalys, visit vectalys.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vectalys compare?

A PDF of Vectalys and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vectalys soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vectalys

Vectalys is a biotech startup founded in 2005 by Pascale Bouillé, specializing in gene delivery through lentiviral vectors. With a dedicated team of 25 full-time employees, Vectalys provides lentiviral vectors, cell models, molecular biology strategies, and project support to scientists globally. The company's advanced proprietary technology ensures top-quality lentiviral vectors, enabling efficient transduction of challenging cells like primary cells, stem cells, and in vivo tissues. Vectalys offers 100% transduction efficiency and non-toxic transduction across various target cells, making it ideal for creating predictive models. The company also customizes lentiviral vectors for specific applications and genes of interest. Additionally, Vectalys manufactures highly pure, ready-to-use lentiviral vectors carrying fluorescent, bioluminescent, or gene-editing proteins for global distribution, saving time and supporting ambitious scientific projects. The startup raised €1.50M in its last Venture Round investment on 13 June 2017 with Auriga Partners as the investor. Vectalys is pioneering excellence in gene delivery to empower groundbreaking scientific discovery and therapeutic development worldwide within the industries of biotechnology, health and wellness, and manufacturing.

Business keywords: gene delivery, lentiviral vectors, biotech company, molecular biology, scientific discovery, therapeutic development, cell models, proprietory technology, transduction efficiency, custom vectors, fluorescent proteins, bioluminescent proteins, gene editing, primary cells, stem cells

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €1.50M 1
Auriga Partners
Auriga Partners
13 Jun 2017
Grant €50.00K 1
EASME - EU Executive Agency for SMEs
03 Jan 2017
Venture Round €900.00K 2
GALIA GESTION
GALIA GESTION, WiSEED
29 Jun 2016
Seed Round €250.00K 1
Ibrahim Soua
18 May 2015
Series B €1.20M 1
Fa Diese
Fa Diese
16 Apr 2012
Series A €1.10M 1
Fa Diese
Fa Diese
26 May 2010

Vectalys Alternatives & Competitors

View All Alternatives
Vectalys vs
Altheia Science
Altheia Science Italy

Altheia Science develops treatments for autoimmune diseases and cancer using innovative tools. Found...

Series A
6 employees
Biotechnology, Health Care
Vectalys vs
Edity Therapeutics
Edity Therapeutics Israel

Using human immune cells to deliver therapeutic proteins

Seed
22 employees
Biotechnology, Health and Wellness
Vectalys vs
Prolific Machines
Prolific Machines United States

Illuminating biology's limitless potential

Series B
65 employees
Biotechnology, Health Care
View all alternatives

FAQ About Vectalys

Pioneering excellence in gene delivery to empower groundbreaking scientific discovery and therapeutic development worldwide.
Vectalys was founded in 2005.
Vectalys operates in Biotechnology, Health and Wellness and Manufacturing. Its work centres on gene delivery, lentiviral vectors, biotech company and molecular biology.
Vectalys has completed 6 funding rounds, raising a total of $5.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Vectalys include Altheia Science, Edity Therapeutics , Prolific Machines, COARE Biotechnology, TreeFrog Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vectalys and Altheia Science are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vectalys, https://bouncewatch.com/company/vectalys, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes